KDM1A and neoplasm: Recently, the first-ever published phase I clinical trial on LSD1 inhibitor-coupled chemotherapy (phenelzine combined with nab-paclitaxel) in metastatic breast cancers was assessed to be safe with the potential for eliminating circulating tumor cells (CTC) with aggressive mesenchymal phenotype [110].